Evidence map›Paper›PMID 29622867›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2018

Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India.

Pankaj Malhotra, Uday Yanamandra, Alka Khadwal, Gaurav Prakash, Deepesh Lad, Arjun D Law, Harshit Khurana, M U S Sachdeva, Praveen Bose, Reena Das and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Intensive care unit admission rates and factors associated following Autologous stem cell transplantation-real-world experience from a tertiary center in rural India.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Cost of HSCT in a Tertiary Care Public Sector Hospital in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantation-A Single Centre Experience.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019
    Article
  13. Stem Cell Transplantation in Multiple Myeloma: Very Much Alive and Kicking.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019
    Article
  14. Highlights of Abstracts on Hematopoietic Stem Cell Transplant in Annual Conference of ISHBT 2018.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019
    Review
  15. Myeloma at Cross Roads in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018
    Article
  16. Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018
    Article
  17. Hematopoietic Stem Cell Transplantation in India-2017 Annual Update.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Pankaj Malhotra1Clinical Haematology Division, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Uday Yanamandra2Department of Haematology and Stem Cell Transplant, Army Hospital (Research and Referral), Delhi, 110010 India.
Alka Khadwal1Clinical Haematology Division, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Gaurav Prakash1Clinical Haematology Division, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Deepesh Lad1Clinical Haematology Division, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Arjun D Law3Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON Canada.
Harshit Khurana4Department of Internal Medicine, Command Hospital (Air Force), Bangalore, India.
M U S Sachdeva5Department of Haematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Praveen Bose5Department of Haematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Reena Das5Department of Haematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Neelam Varma5Department of Haematology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Subhash Varma1Clinical Haematology Division, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012 India.
Post Graduate Institute of Medical Education and Research · INArmy Hospital Research and Referral · INCommand Hospital Air Force · INPrincess Margaret Cancer Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous stem cell transplantation (ASCT) is considered as standard of care in patients with multiple myeloma (MM) patients aged 65 years or younger. We analyzed data of 94 patients of plasma cell dyscrasias who underwent 95 autologous transplants at our institute from October 2003 to Aug 2016. Other than 76 patients of newly diagnosed multiple myeloma, we also transplanted two patients of POEMS syndrome, two patients of plasma cell leukemia, three patients of concurrent light chain deposition disease, three patients of multifocal plasmacytomas, and eight patients of isolated light chain myeloma. One patient underwent transplant twice. The median age of patients was 53 years (range 21-65). The average interval between diagnosis and transplant was 10.51 ± 5.42 months. The predominant stage in the study cohort was ISS-III. IgG kappa was the commonest subtype of plasma cell dyscrasia (27.9%) followed by IgG lambda (16.27%). Renal involvement was seen in 25% patients at the time of transplantation. Following chemotherapy, 42% patients were in CR, 39% in VGPR, 5% had PR and 14% had progressive disease at the time of transplantation. All patients were conditioned with melphalan (dose 120-200 mg/m

Indexed as

ASCTAutologousMyelomaReal WorldTransplant

Identifiers

PMID29622867
PMCPMC5884990
OpenAlexW2755035768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.